AZN

Thinking of Investing in AZN? What Our Analysts Know.

AstraZeneca PLC logged a -2.5% change during today's afternoon session, and is now trading at a price of $68.73 per share. The S&P 500 index moved 0.9%. AZN's trading volume is 5,547,686 compared to the stock's average volume of 4,832,075.

AstraZeneca PLC trades -10.4% away from its average analyst target price of $76.71 per share. The 7 analysts following the stock have set target prices ranging from $65 to $88, and on average have given AstraZeneca PLC a rating of buy.

If you are considering an investment in AZN, you'll want to know the following:

  • AstraZeneca PLC's current price is 460.0% above its Graham number of $12.27, which implies that at its current valuation it does not offer a margin of safety

  • AstraZeneca PLC has moved 19.3% over the last year, and the S&P 500 logged a change of -11.3%

  • Based on its trailing earnings per share of 0.64, AstraZeneca PLC has a trailing 12 month Price to Earnings (P/E) ratio of 107.4 while the S&P 500 average is 15.97

  • AZN has a forward P/E ratio of 18.8 based on its forward 12 month price to earnings (EPS) of $3.66 per share

  • The company has a price to earnings growth (PEG) ratio of 1.33 — a number near or below 1 signifying that AstraZeneca PLC is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 6.1 compared to its sector average of 4.07

  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.

  • Based in Cambridge, the company has 83,100 full time employees and a market cap of $214,914,416,640. AstraZeneca PLC currently returns an annual dividend yield of 4.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS